I believe you have highlighted the key aspects of this new presentation.
"Administration of Low-Dose, Subcutaneous (SC) Interleukin-2 (IL-2) Markedly Enhances the Pharmacokinetic (PK) Profile of Azercabtagene Zapreleucel(azer-cel) ... without Compromising Safety"
Even if no new data are presented at this poster session, we should learn a lot more about the interaction between IL-2 and acer-cel. In my view, this will be very important. As correctly noted by others, 'pharmacokinetics' is all about how a drug is 'handled' by our bodies ... in others words its absorption, distribution, metabolism and excretion. If IMU are stating that IL-2 markedly enhances this process, then the treatment (azer-cel) is very likely to be more effective. Simples.
Leslie recently wrote ...
"In Cohort B, comprising four patients who receivedazer-cel with both lymphodepletion (chemotherapy) andinterleukin 2 (IL-2), we saw even more promising results.Two patients achieved complete responses, with onemaintaining this response for over 120 days and the otherfor over 90 days. The encouraging safety profile and thepotential enhanced durability of responses with IL-2have prompted us to consider incorporating this regimeninto a Phase 2/3 trial package for FDA evaluation".
I suggest that punters don't overlook this session because we will not be seeing the next data cut. We could very well see some very valuable information, especially if the addition of interleukin 2 enhances the performance of acer-cel without compromising safety !
Just my quick thoughts, 'on the fly'. Opinion only.
IMU Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)